一种新的HCN2功能丧失变异,导致发育性和性脑病变,用性饮食治疗
Jacopo C DiFrancesco1, Francesca Ragona2, Carmen Murano3
1Department of Neurology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Epilepsia
|September 25, 2023
概括
一种新的HCN2基因变异导致发育性和性脑病变 (DEE). 这项研究详细介绍了一名由于新的HCN2突变而患有DEE的患者,强调了性饮食.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 离子通道生理学 离子通道生理学
背景情况:
- 超极化激活的循环核酸 (HCN) 离子通道中的误解变异与综合征有关,包括发育性和性脑病变 (DEE).
- 虽然HCN1变种是DEE的已知的原因,但HCN2变种主要与一般性有关.
- 在DEE中导致HCN通道功能障碍的精确机制仍然是活跃的研究领域.
研究的目的:
- 报告第一个由HCN2基因中的新型异构合误解变异引起的DEE病例.
- 为了功能性地描述已识别的HCN2变体 (p.G460D),并阐明其对通道功能和细胞局部化的影响.
- 调查HCN2变体对HCN1-HCN2异构体功能的影响,并探索基因饮食的治疗潜力.
主要方法:
- 基因测序以确定DEE患者的变异.
- 在体外电生理学记录 (HEK293细胞,新生小鼠皮质神经元) 来评估HCN2通道功能.
- 免疫光染色以确定通道局部.
- 在 ketogenic 环境中进行体外实验,以评估饮食影响.
主要成果:
- 在HCN2中发现了一种新的新型异合误解变异,c.1379G>A (p.G460D),被确定为该患者DEE的原因.
- HCN2 p.G460D 变体导致离子电流显著减少,表明主导负功能丧失效应.
- 突变的HCN2通道在细胞内被保留,无法到达血,HCN1-HCN2异构体功能受损.
- 性饮食导致了发作频率的显著和持续减少,尽管体外研究表明这不是由于HCN2活性的直接调节.
结论:
- 这项研究扩大了HCN2通道病变的临床谱,确定了与DEE相关的新型变异.
- 这些发现阐明了DEE中HCN2功能障碍的分子机制,包括受损的通道功能,贩运和异构化.
- 性饮食在这个患者中显示出治疗效果,这表明它在管理特定的HCN2相关综合征方面的潜在作用,独立于直接的HCN2调制.
相关概念视频
Inborn Errors of Metabolism
179
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
179
Antiepileptic Drugs: GABAergic Pathway Potentiators
446
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
446
Antiepileptic Drugs: Glutamate Antagonists
407
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
407
Antiepileptic Drugs: Potassium Channel Activators
203
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
203
Seizures: Classification
396
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
396
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
332
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
332


